Landmark cardiovascular outcome trials have shown a benefit of SGLT2 inhibitors over placebo in the composite endpoint of cardiovascular mortality or HF hospitalizations [8], [9], [10], [11], [12], [13], [14], [15]. This evidence concerns the gene SLC5A2 and hydrops fetalis.